By Investing.com Staff
After-hours stock movers:
IsoPlexis (NASDAQ:ISO) 107% HIGHER; Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis, a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.
Lexicon Pharmaceuticals (NASDAQ:LXRX) 10% LOWER; announced topline results of RELIEF-PHN-1, its Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 from baseline at week 6 compared to a reduction of 1.62 in the placebo arm, with a placebo adjusted difference of 0.80 (p=0.12). Although these results did not reach statistical significance on the primary endpoint of the study, overall study results demonstrated clear evidence of effect. Separation of LX9211 from placebo on ADPS was seen at week 1 and maintained consistently thereafter, with an average placebo adjusted reduction over the 6 Week dosing period of 0.80 (p=0.03).
Micron Technology (NASDAQ:MU) 2% LOWER; reported Q1 EPS of ($0.04), below the analyst estimate of ($0.01). Revenue for the quarter came in at $4.09B versus the consensus estimate of $4.15B. Micron Technology sees Q2 2023 EPS of ($0.72)-($0.52), versus the consensus of ($0.30). Micron Technology sees Q2 2023 revenue of $3.6B - $4B, versus the consensus of $3.75B.
Mirati Therapeutics (NASDAQ:MRTX) 2% HIGHER; announced today that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy. This designation is supported by results from the Phase 1b cohort of the KRYSTAL-1 trial.
Applied Materials (NASDAQ:AMAT) 2% LOWER; falls following results and guidance from Micron.
Lam Research Corp (NASDAQ:LRCX) 2% LOWER; falls following results and guidance from Micron.